Other, Publications, XMT-1522

Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.

September 2019

Dolaflexin, DolaLock, Publications, XMT-1522

Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.

November 2018

Dolaflexin, DolaLock, Publications, XMT-1522

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric cancer

June 2018

Dolaflexin, DolaLock, Publications, XMT-1522

Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 mAb in a syngeneic breast cancer model expressing human HER2

April 2018